Journal Club 01 - All about breast cancer

Thursday, July 23, 2020

While relaxing on the Jersey Shore, host and MDedge Hematology/Oncology Editor-in-Chief David Henry, MD, dove into the July 10, 2020, issue of the Journal of Clinical Oncology. In episode 82, we do the same.

J Clin Oncol. 2020 Jul 10. 38(20). 2217-2361. (

You can follow along with the following articles:

  1. Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact (

  2. Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation (
  3. Partial Breast Irradiation Is the Preferred Standard of Care for a Majority of Women With Early‐Stage Breast Cancer (
  4. Whole-Breast Irradiation Is the Preferred Standard of Care for the Majority of Patients With Early-Stage Breast Cancer (
  5. Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery (
  6. Locoregional Management After Neoadjuvant Chemotherapy (

For more MDedge Podcasts, click this link:

Email the show: [email protected]

Follow Dr. David Henry on Twitter @DavidHenryMD

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.